MC2 Therapeutics turns back on eye treatment to focus on skin

The Danish biotech company is no longer expecting to bring its most advanced candidate against dry eyes through upcoming testing alone, as it intensifies its focus on developing skin treatments.

Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics / PR

MC2 Therapeutics is streamlining its pipeline, a move that has left one of the company’s most advanced drug candidates, a potential treatment for a disease that causes dry eyes, Sjögren’s syndrome, out in the cold, reports Danish business daily Børsen.

The candidate is moving down the company’s agenda despite facing an important trial. Instead of running the study itself, MC2 is now looking for a partner:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs